





**Supplementary Figure S1: H&E staining of liver, kidney and spleen collected from mice bearing 786-O xenografts.** No significant morphological changes were observed due to treatment. Bar length = 200  $\mu$ m.





**Supplementary Figure S2: H&E staining of liver, kidney and spleen collected from mice bearing A498 xenografts.** No significant morphological changes were observed due to treatment. Bar length = 200  $\mu$ m.



**Supplementary Figure S3: Single mouse trial demonstrating the anti-PD-1 therapy resistance of Renca mouse model used in this study.** Both anti-PD-1 antibody and PD-1/PD-L1 small molecule inhibitor did not show any tumor growth inhibitory effect. EG-L did not show any additive or synergistic effect when combined with anti-PD-1 therapy either. In fact, anti-PD-1 therapy seemed to exert slight antagonistic effect to EG-L treatment in the long run. (n= 1 mouse per treatment group)



**Supplementary Figure S4: Effect of EG-L treatment on the expression of PD-1 in Renca tumors.** EG-L treatment did not significantly change PD-L1 (A,B) or PD-1 (C,D) expression in the Renca tumors compared to the vehicle treated tumors. N.S. means not significant. (n = 3 tumors for control and 5 tumors for EG-L)



**Supplementary Figure S5: Uncropped blots showing the bands of the respective target proteins used in Figure S4.**  
The merged images show the bands along with the markers (M).

Target	Forward Primer	Reverse Primer
CXCL9 (m)	5'-TGTGGCTGTAGCTTAGTGGC-3'	5'-GCCAATGCCTGGTGTGTAAC-3'
CXCL10 (m)	5'-ATGACGGGCCAGTGAGAATG-3'	5'-CTCCCCAGACCACCATTTC-3'
CXCL11 (m)	5'-AGCCACCCAAAGCTAGGAAC-3'	5'-CCTGCCTCCCTCACATAACC-3'
TGFB1 (m)	5'-TCCTAACCCAGAGGTGGAC-3'	5'-CCGAAATTCTGCGTCTGCTG-3'
ACTB (m)	5'-GGCACCACACCTTCTACAATG-3'	5'-GGGGTGTTGAAGGTCTCAAAC-3'

**Supplementary Table S1: Primer Sequences used in this study.**